Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development

Reuters

Oct 20

Chugai Signs License Agreement With Rani <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for Oral Biologics Development

Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576004464"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576004464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576004464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576004464","market":"nz","top_or_hot":-1,"title":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 07:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RANI","symbol_name":"Rani Therapeutics Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDLbr50Ry:1","article_id":"2576004464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576004464","pubTimestamp":1760916838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RANI":"Rani Therapeutics Holdings","BK4539":"次新股","BK4007":"制药"},"translate_title":"中外制药与Rani Therapeutics签署口服生物制剂开发许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RANI":0.9},"content_text":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n    \n\nChugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}